| Literature DB >> 27590668 |
Jennifer Stinson1,2, Sara Ahola Kohut3, Paula Forgeron4, Khush Amaria3, Mary Bell5, Miriam Kaufman6, Nadia Luca7, Stephanie Luca8, Lauren Harris8, Charles Victor9, Lynn Spiegel10.
Abstract
BACKGROUND: Adolescents with Juvenile Idiopathic Arthritis (JIA) are at risk for physical, emotional, social and role challenges that negatively impact quality of life. Peer mentoring has been shown to improve positive health behaviours in adolescents with chronic disease while simultaneously providing social support. The objectives of this paper are to examine the feasibility and acceptability of an online peer mentoring program (iPeer2Peer Program) for adolescents with JIA.Entities:
Keywords: Adolescents; Juvenile Idiopathic Arthritis; Randomized controlled trial; Social support
Mesh:
Year: 2016 PMID: 27590668 PMCID: PMC5010693 DOI: 10.1186/s12969-016-0108-2
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Fig. 1Study flow diagram
Demographic and disease characteristics of participants and mentors
| Characteristic | iPeer2Peer program | Control |
|---|---|---|
|
|
| |
| Participants (total | 18a | 14 |
| Age, mean ± SD years | 14.11 ± 1.53 | 14.42 ± 2.04 |
| Grade, mean ± SD | 9.11 ± 1.57 | 9.50 ± 2.21 |
| Sex | ||
| Female | 17 (94) | 14 (100) |
| Male | 1 (6) | 0 (0) |
| Diagnosis | ||
| Polyarthritis (RF positive) | 3 | 3 |
| Polyarthritis (RF negative) | 3 | 3 |
| Polyarthritis (RF status unknown) | 1 | 0 |
| Oligoarthritis | 5 | 5 |
| Psoriatic Arthritis | 6 | 2 |
| Juvenile Enthesitis-related Arthritis | 0 | 1 |
| Systemic Arthritis | 0 | 0 |
| Disease Activity, mean ± SD, range = 0–10b | 1.71 ± 2.81 | 1.27 ± 1.10 |
| Duration since diagnosis, mean ± SD years; Duration since diagnosis, range | 7.86 ± 4.85 | 7.30 ± 4.78 |
| <1 month–14.16 years | 1.25–15.65 years | |
| Mentors ( | ||
| Age, mean ± SD years | 18.88 ± 1.48 | |
| Sex | ||
| Female | 5 (83) | |
| Male | 1 (17) | |
| Diagnosis | ||
| Polyarthritis (RF negative) | 3 (50) | |
| Oligoarthritis | 1 (17) | |
| Psoriatic Arthritis | 1 (17) | |
| Systemic Arthritis | 1 (17) | |
| Duration of illness, mean ± SD years | 8.52 ± 6.40 | |
| Number of mentees, mean ± SD | 3.60 ± 2.97 | |
| Number of mentees, range | 1–8 | |
Notes. aAll participants, including the post control iPeer2Peer Program participants (n = 2). bDisease activity is measured via a physician global assessment visual analog scale
Fig. 2Topics discussed during ipeer2peer program video calls
Sample quotations from participant post-iPeer2Peer program interviews
| Female; 14 years old |
|
| Female; 13 years old |
|
| Female; 15 years old |
|
| Female; 12 years old |
|
| Male; 16 years old |
|
Secondary outcomes for participants by treatment condition
| Variable | Experimental group | Control group | Test statistics |Z| |
| Effect size |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | (Cohen’s d) | |||
| ( | ( | ||||
| Pain Intensity (average; range = 0–10, higher scores = higher pain intensity) | 0.48 | 0.63 | 0.06 | ||
| Pre-treatment | 2.39 (2.06) | 2.43 (2.65) | |||
| Post-treatment | 2.06 (1.83) | 2.21 (1.97) | |||
| Self-Efficacy (CASES; range = 11–55, higher scores = greater efficacy) | 0.07 | 0.95 | 0.29 | ||
| Pre-treatment | 37.28 (12.22) | 39.57 (11.10) | |||
| Post-treatment | 40.28 (12.52) | 40.07 (12.83) | |||
| PedsQL pain (range = 0–100, higher scores = lower problems) | 0.63 | 0.53 | 0.04 | ||
| Pre-treatment | 65.63 (21.68) | 61.16 (26.19) | |||
| Post-treatment | 67.36 (22.84) | 62.05 (28.95) | |||
| PedsQL activities (range = 0–100, higher scores = lower problems) | 0.64 | 0.76 | 0.07 | ||
| Pre-treatment | 87.50 (20.81) | 87.14 (22.08) | |||
| Post-treatment | 88.06 (18.88) | 86.79 (22.33) | |||
| PedsQL tx (range = 0–100, higher scores = lower problems) | 0.98 | 0.33 | 0.33 | ||
| Pre-treatment | 72.22 (21.69) | 73.98 (14.25) | |||
| Post-treatment | 70.44 (17.62) | 76.28 (15.51) | |||
| PedsQL worry (range = 0–100, higher scores = lower problems) | 0.34 | 0.73 | 0.19 | ||
| Pre-treatment | 62.50 (29.32) | 55.95 (23.89) | |||
| Post-treatment | 62.96 (29.60) | 60.71 (30.74) | |||
| PedsQL comm (range = 0–100, higher scores = lower problems) | 0.33 | 0.74 | 0.23 | ||
| Pre-treatment | 63.89 (26.51) | 62.50 (19.27) | |||
| Post-treatment | 63.89 (30.65) | 67.26 (24.78) | |||
| MEPS_total (range = 0–230, higher scores = higher perceived ability) | 2.10 | 0.036 | 0.72 | ||
| Pre-treatment | 130.56 (36.98) | 137.64 (26.58) | |||
| Post-treatment | 140.50 (30.31) | 128.57 (30.93) | |||
| MEPS_knowledge (range = 0–90, higher scores = higher perceived ability) | 1.47 | 0.14 | 0.28 | ||
| Pre-treatment | 45.56 (19.17) | 45.57 (15.55) | |||
| Post-treatment | 47.78 (15.39) | 44.00 (12.34) | |||
| MEPS_exercise (range = 0–40, higher scores = higher perceived ability) | 0.56 | 0.53 | 0.51 | ||
| Pre-treatment | 26.50 (9.34) | 31.57 (8.81) | |||
| Post-treatment | 27.56 (8.23) | 28.79 (10.70) | |||
| MEPS_pain (range = 0–60, higher scores = higher perceived ability) | 2.11 | 0.035 | 0.74 | ||
| Pre-treatment | 37.72 (11.87) | 40.29 (11.45) | |||
| Post-treatment | 41.22 (12.24) | 35.50 (12.83) | |||
| MEPS_social (range = 0–40, higher scores = higher perceived ability) | 1.28 | 0.20 | 0.38 | ||
| Pre-treatment | 20.78 (6.37) | 20.21 (4.81) | |||
| Post-treatment | 23.94 (6.49) | 20.29 (6.91) | |||
Note. Analysis has been adjusted to account for period of observation and baseline scores of the same measure